Clinical Trials
139 trialsNCT02297438 2026-05-14
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT01298323 2026-04-17
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
Phase 3 Completed
NCT01630733 2026-04-15
ENSPIRIT
Achieve Life Sciences
Phase 3 Completed
NCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT02000622 2026-02-13
OlympiAD
AstraZeneca
Phase 3 Completed
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT03257267 2025-04-08
Study of Cemiplimab in Adults With Cervical Cancer
Regeneron Pharmaceuticals
Phase 3 Completed
NCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT01740427 2024-11-14
PALOMA-2
Pfizer
Phase 3 Completed
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT00365105 2024-09-20
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04799249 2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3 Completed
NCT03306394 2024-07-25
PRECONNECT
Servier
Phase 3 Completed
NCT01231347 2024-07-16
GAMMA
NantCell, Inc.
Phase 3 Completed
NCT02049905 2024-06-13
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
Phase 3 Completed
NCT03764293 2024-02-06
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04887506 2024-01-16
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
Phase 3 Completed
NCT00606866 2023-11-29
MRI
University of Chicago
Phase 3 Completed
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT00002872 2023-06-22
Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00128310 2023-05-31
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT00113763 2022-11-07
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT02460419 2022-10-28
Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT01001377 2022-09-21
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00377156 2022-09-16
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01372774 2022-09-16
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01668784 2022-08-09
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Bristol-Myers Squibb
Phase 3 Completed
NCT00039780 2022-07-13
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
BioNumerik Pharmaceuticals, Inc.
Phase 3 Completed
NCT03042611 2022-07-08
ANGEL
Elevar Therapeutics
Phase 3 Completed
NCT01307878 2022-06-14
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases
Fudan University
Phase 3 Completed
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT00116142 2022-01-11
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Dana-Farber Cancer Institute
Phase 3 Completed
NCT00134056 2021-10-27
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT00369785 2021-10-20
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Wake Forest University Health Sciences
Phase 3 Completed
NCT00005887 2021-08-23
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT00324727 2021-06-21
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Delcath Systems Inc.
Phase 3 Completed
NCT02111577 2021-04-06
VIABLE
Sotio Biotech Inc.
Phase 3 Completed
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
NCT02264990 2021-02-26
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
AbbVie
Phase 3 Completed
NCT03061812 2021-02-23
TAHOE
AbbVie
Phase 3 Completed
NCT01694277 2020-12-08
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
Phase 3 Completed